Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450106 · ClinicalTrials.gov registry record · Phase 1

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

A Phase 1 study of Prostate Cancer, sponsored by SURGE Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
4
Study locations

NCT06450106: Recruiting Phase 1 study of Prostate Cancer, sponsored by SURGE Therapeutics.

NCT06450106 is a Phase 1 study of Prostate Cancer that is actively recruiting participants, run by SURGE Therapeutics. The registered enrollment target is 18 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450106, a Phase 1 study of Prostate Cancer, is actively recruiting participants, sponsored by SURGE Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
4
Study locations

Study Summary

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Primary Outcome

Incidence of dose-limiting toxicities (DLTs) over the first 21-days of study treatment

Conditions Studied

Prostate Cancer

Interventions

  • DRUG STM-416p

Study Locations (4)

Victoria

  • Australian Prostate Center - Melbourne N.
  • Epworth HealthCare - Melbourne N.

Arizona

  • Arizona Urology Specialists - Tucson

Florida

  • University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-05-08
Est. Completion 2026-12
Phase Phase 1
SURGE Therapeutics

3 total trials

What NCT06450106 shows while recruiting

NCT06450106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which STM-416p is the first listed.

NCT06450106 reports a single indexed study location in Victoria, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT06450106 about?

NCT06450106 is a clinical study titled "Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy". A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

What is the current status of trial NCT06450106?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-05-08. Estimated completion is 2026-12.

What conditions does trial NCT06450106 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06450106?

The interventions under investigation include: STM-416p (DRUG).

Who is sponsoring clinical trial NCT06450106?

This trial is sponsored by SURGE Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450106 being conducted?

This trial has 4 study locations across Arizona, Florida, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06450106's enrollment target sits among peer trials

18 675th of 735 higher than 56 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06450106

Source: ClinicalTrials.gov NCT06450106, the US trial registry maintained by the National Library of Medicine. NCT06450106 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.